Your SlideShare is downloading. ×
CM adultas autologas en Peru
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

CM adultas autologas en Peru

523
views

Published on

Published in: Education

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
523
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
14
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Células MadreStemCells
    Usoterapéutico de lascélulasmadre en Perú.
    Tamara Jorquiera, MC
  • 2. Células Madre
    Inmaduras
    Con capacidad para regenerar
    REPARAN
    Auto renovación
    Diferenciación
  • 7. Mantener un pool constante
    Para crear en el desarrollo o para reparar en el adulto
  • 8. Clasificación
    Mórula
    CP Fetales/Adultas
    Ej. CP Hematopoyéticas
    CP Adultas
    Ej. CP Satélite (Musc)
    Células Ovales (Hígado)
    CP Embrionarias
    CP presentes en todas las etapas del desarrollo, pero con diferente potencialidad (Concepto Tradicional)
    TotipotentesPluripotentesMultipotentesMonopotentes
  • 9. Blástula
    Mórula
    4to día
    5to día
  • 10. EmbrionariasNO USAMOSs
    Blástula
    Desarmar el embrión
    In 1998, researchersfromtheuniversity of Wisconsin isolatedstemcellsfromIVF-blastocysts.
  • 11.
  • 12. Problemas para el uso clínico de células madre embrionarias
    Capacidad de inducción de tumores
    Rechazo (diferencias en los antígenos de histocompatibilidad entre embrión y receptor)
    Necesidad de inmunosupresión o clonación
    Necesita mucha tecnología
    (mayor costos para el manejo)
  • 13. Células Madre Adultas
  • 14. 10
    CP utilizadashace > 30 años en (TMO)
    10
  • 15. Fuentes de CM Adultas
    Médula Ósea: Múltiples tipos de células madre
    Sangre venosa periférica: las células son movilizadas hacia la sangre periférica utilizando Factores de crecimiento (G-CSF) y luego colectadas por aféresis
    Sangre de Cordón Umbilical: “semejantes” a las de la MO, son colectadas al momento del parto
    Líquido amniótico
    Placenta
    Grasa
  • 16.
  • 17.
  • 18. Obtención
  • 19. Centrífuga
  • 20. Leucoconcentración
    Plasma
    MIAMI
    VSEL
    Mononucleares
    CPE
    Mesenquimales
    Glóbulos rojos
    Hemangioblatos
    MAPCs
  • 21. Hematopoyética
    VSEL
    MIAMI
    Mesenquimal
    C. Progenitoras Endoteliales
    MAPC
    MIAMI
    VSEL
    CPE
    SC mesenquimales
    A population of very small embryonic-like (VSEL) CXCR4þSSEA-1þOct-4þ stem cells identified in adult bone marrow
    M Kucia, R Reca, FR Campbell, E Zuba-Surma, M Majka, J Ratajczak and MZ Ratajczak
    Hemangioblatos
    MAPCs
  • 22. Preliminary Evidence of Plasticity Among Nonhuman Adult Stem Cells. NIH USA
    T
    D
    T
    D
    D
    Diferenciación
    D
    T
    D
    T
    Transdiferenciación
  • 23.
  • 24. Bibliografía
    Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice
    Eglitis MA, et al. Proc Natl Acad Sci U S A 1997;94:4080-5
    Muscle regeneration by bone marrow-derived myogenic progenitors
    Ferrari G, et al.Science 1998;279:1528-30
    Turning brain into blood: a hematopoietic fate adopted by adult neuronal stem cells in vivo
    Bjornson CR, et al.Science 1999;283:534-7
    Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow
    Mezey E, et al.Science 2000;290:1779-82
    Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
    Lagasse E, et al. Nat Med 2000;6:1229-34
    Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity
    Joshua M. Harea PNAS, August 18, 2009, vol. 106 no. 33, p. 14022–27
  • 25. Theise ND, et al. Hepatology 2000Alison MR, et al. Nature 2000
    Hepatocito
    XX
    Evidencia en seres humanos
    Trasplantes de MO
    Receptor
    Receptor
    Donante
    XY
    XY
    XX
  • 26. Cardiomiocito
    Laflamme MA, et al. Circ Res 2002Quaini F, et al. N Engl J Med 2002Minami E, et al. Circulation 2005
    Evidencia en seres humanos
    Trasplantes de órganos sólidos
    Receptor
    Donante
    Donante
    XY
    XX
    XY
    XY
  • 27. Células Madre que normalmente salen y migran hacia tejidos lesionados, para ayudar en la reparación de tejidos.
     HOMING
    Guiadas por señales químicas de inflamación.
    AMPLIAR este mecanismo.
    Células madre
    ADULTAS
    AUTÓLOGAS
    con mínima manipulación
    Médula Ósea
  • 28. Mecanismos de Acción
  • 29.
  • 30.
  • 31.
  • 32. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Joshua M. Harea, PNAS, August 18, 2009, vol. 106 no. 33, p. 14022–27
    Perpetuán el estímulo
  • 33. Stem cells show potential for many different areas of health and medical research, and studying them can help us understand how they transform into the dazzling array of specialized cells that make us what we are. Some of the most serious medical conditions, such as cancer and birth defects, are caused by problems that occur somewhere in this process. A better understanding of normal cell development will allow us to understand and perhaps correct the errors that cause these medical conditions.
    Research on one kind of stem cell—human embryonic stem cells—has generated much interest and public debate. Pluripotent stem cells (cells that can develop into many different cell types of the body) are isolated from human embryos that are a few days old. Pluripotent stem cell lines have also been developed from fetal tissue (older than 8 weeks of development).
    As science and technology continue to advance, so do ethical viewpoints surrounding these developments. It is important to educate and explore the issues, scientifically and ethically.
    For More Information:
    The following links to other Internet sites are offered only for the convenience of World Wide Web users. The NIH is not responsible for the availability or content of these external sites, nor does the NIH endorse, warrant, or guarantee the products, services, or information described or offered at these other Internet sites.
    Research Ethics and Stem Cells
  • 34. Presidential Commission on Bioethics The Presidential Commission for the Study of Bioethical Issues advises President Obama on bioethical issues that may emerge from advances in biomedicine and related areas of science and technology.
    National Academy of Sciences Guidelines for Human Embryonic Stem Cell Research The National Academy of Sciences developed its first set of ethical standards for stem cell research in 2005.  The guidelines were updated in 2007, 2008, and 2010.
    The Kennedy Institute of Ethics at Georgetown University Library & Information Services allows searches of books, newspapers, journal articles, and other materials on bioethical issues.
    Stem Cell Research and Applications: Monitoring the Frontiers of Biomedical Research(300K PDF; get Adobe Reader) The American Association for the Advancement of Science (publisher of Science magazine) and the Institute for Civil Society produced this report addressing stem cells and ethics.
    The Ethics of Human Embryonic Stem Cell Research The International Society for Stem Cell Research provides this information as a public service to those wishing to discuss stem cell ethics.
    Report On Human Embryonic Stem Cell Research from the European Union (1.5MB PDF; get Adobe Reader)
    Bioethics Advisory Committee (BAC) Singapore Addresses the ethical, legal, and social issues arising from biomedical sciences research.
  • 35. ¿Qué tratamos con Células Madre?
  • 36. PARKINSON
  • 37. 33
    33
  • 38. ¿A quienes se le puede hacer?
    < 80 años
    Sin demencia no podrá hacer rehabilitación.
    Sin otras enfermedades complicadas: Hipertensión, Diabetes.
  • 39. 50 pacientes con buen seguimiento
  • 40.
  • 41. STROKE – ACV – Infarto CerebralHipoxia cerebralFalta de oxígeno en cerebro
  • 42. EXPERIENCIA
    INFARTOS CEREBRALES:
    -1 pacientes con 18 años de infarto
    -1 paciente con 4a de infarto cortical -1 paciente con 6 meses de ACV
    -1 paciente con 3 meses de infartotroncal
  • 43. IMPLANTE DE CÉLULAS MADRESPECT pre implante y control 5 m 4a enf.
  • 44. Manejo del Stroke Agudo
    con Stem Cells
    CONCLUSION:
    • El implante intra-arterial selectivo es eficiente y seguro en fase aguda de un ACV
    • 45. Estudios futuros son necesarios para evaluar la eficiencia del implante de celulas madre.
    • 46. La presencia de células madre marcada con TC 99m a las 4 horas después del trasplante sugiere pasaje de estas células por la barrera hematoencefálica
    • 47. La imagen PET-FDG sugiere la presencia de células madre metabólicamente vivas a los 7 dias post implante de las Células Madre
    Dr. Hans Dohman - Brazil
    II Congreso de Terapia Celular del Pacífico Sur
    Agosto 2006 Lima, Perú
  • 48. SPECT Cerebral
    BASAL
    7 DIAS POST
    6 MESES POST
    5to dia post
    infarto
    7imo dia post
    implante CM
    Manejo del Stroke Agudo
    con Stem Cells
    7mo dia post
    implante CM
    5to dia post
    infarto
    16avo dia post
    implante CM
    Dr. Hans Dohman - Brazil
    II Congreso de Terapia Celular del Pacífico Sur
    Agosto 2006 Lima, Perú
  • 49. CIRROSIS
  • 50. CAUSAS?
    Hepatitis
    Alcoholismo
    SÍNTOMAS
    AscitisCirculación periféricaHemorragias
  • 51. CIRROSISALTERNATIVAS DE TRATAMIENTO
    Eliminar las causas.
    Tratar cada síntoma.
    Trasplante de hígado.
    TIPS
    PARACENTESIS
    SHUNT PERITONEO VENOSO
    EMBOLIZACIÓN DE VÁRICES ESOFÁGICAS
  • 52. En Lesión Hepática
    Hepatocitos
    CélulasOvales
    CM de médulaósea
    CM de médulaósea
    Leve
    Moderada
    Severa
    Muysevera
    Inhibición de la proliferación de hepatocitos
    • Hematopoieticstemcelltrafficking in liverinjury, EvangelosDalakas, The FASEB Journal
  • 53. ENFERMEDAD VASCULAR PERIFÉRICA
  • 54. Patient # 1
    Angio Pre Implante
    Angio Post Implante
    11 MESES
    1 MES
    PRE
  • 55. ENFERMEDAD CARDIACAInfarto

×